ArticleVirus research2008
Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease.
Article in Virus research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 123 citations in OpenAlex.
- Construction and Immunogenicity of a Recombinant Pseudorabies Virus Expressing the Major Neutralizing Epitopes A and D of Transmissible Gastroenteritis Virus Spike Protein.Veterinary sciences · 2026Article
- A recombination-resistant genome for live attenuated and stable PEDV vaccines by engineering the transcriptional regulatory sequences.Journal of virology · 2023Article
- Review
- Vaccine development for zoonotic viral diseases caused by positive‑sense single‑stranded RNA viruses belonging to theExperimental and therapeutic medicine · 2023Review
- Vaccines platforms and COVID-19: what you need to know.Tropical diseases, travel medicine and vaccines · 2022Review
- Immunophenotyping of SARS-CoV-2 and vaccine design.Vaccine · 2022Article
- A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus.Applied microbiology and biotechnology · 2022Article
- Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.Journal of microbiology (Seoul, Korea) · 2022Review
- Covid19 pandemic as a further driver of water scarcity in Africa.GeoJournal · 2022Article
- Perception of COVID-19 and Vaccine Acceptance among Healthcare Workers.International journal of microbiology · 2022Article
- Article
- SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies.International immunopharmacology · 2021Review
- In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes.Archives of Razi Institute · 2021Article
- Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.PLoS biology · 2021Article
- Mouse Adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge.bioRxiv : the preprint server for biology · 2021Article
- Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.Transboundary and emerging diseases · 2021Review
- Current progress and challenges in the design and development of a successful COVID-19 vaccine.Fundamental research · 2021Review
- COVID-19 vaccines: The status and perspectives in delivery points of view.Advanced drug delivery reviews · 2021Review
- Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.3 Biotech · 2021Article
- Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections.Clinical & translational immunology · 2021Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
An important effort has been performed after the emergence of severe acute respiratory syndrome (SARS) epidemic in 2003 to diagnose and prevent virus spreading. Several types of vaccines have been developed including inactivated viruses, subunit vaccines, virus-like particles (VLPs), DNA vaccines, heterologous expression systems, and vaccines derived from SARS-CoV genome by reverse genetics. This review describes several aspects essential to develop SARS-CoV vaccines, such as the correlates of protection, virus serotypes, vaccination side effects, and bio-safeguards that can be engineered into recombinant vaccine approaches based on the SARS-CoV genome. The production of effective and safe vaccines to prevent SARS has led to the development of promising vaccine candidates, in contrast to the design of vaccines for other coronaviruses, that in general has been less successful. After preclinical trials in animal models, efficacy and safety evaluation of the most promising vaccine candidates described has to be performed in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.